Open access peer-reviewed chapter

Lean Women with Polycystic Ovary Syndrome

Written By

Elham Pourmatroud

Submitted: 29 March 2017 Reviewed: 21 August 2017 Published: 20 December 2017

DOI: 10.5772/intechopen.70621

From the Edited Volume

Debatable Topics in PCOS Patients

Edited by Neeraj Kumar Agrawal and Kiran Singh

Chapter metrics overview

1,490 Chapter Downloads

View Full Metrics


Most of the time, polycystic ovary syndrome (PCOs) is considered as an obese women disease; lean PCOs patients need to evaluate and treat completely as a neglected subgroup. Androgen excess signs and symptoms, insulin resistance (IR) and its consequences, cardiometabolic risks, and regular exercise must be noted and managed carefully.


  • lean
  • non-obese
  • androgen
  • insulin
  • PCO

1. Introduction

Polycystic ovary syndrome (PCOs) is the most common reason of androgen excess in reproductive-age women with a prevalence of 6.5–8% according to clinical appearance [1] or even up to 20% by sonographic evidence [2].

For the first time, Stein and Leventhal described it in the year 1935 [3]. Year after year, the description of the disease developed; in 1990, the National Institutes of Health (NIH) mentioned oligo-ovulation and hyperandrogenism with or without hyperandrogenemia (HA) must be together (of course, after exclusion of another causes of androgen excess) [4].

Another expert meeting in 2003 expanded the NIH definition of PCOs by adding the sonographic aspect of the disease (Rotterdam criteria) [5]. According to their criteria, two of three signs/symptoms are necessary for PCOs diagnosis; therefore, PCOs woman can be ovulatory with regular menstruation.

More recently, the Androgen Excess Society (AES) advocated that all of the signs and symptoms should be present for the confirmation of diagnose [6] ( Table 1 ).

NIH Criteria 1990 (all of them) ESHRE 1 /ASRM 2 (Rotterdam) 2003 (two of three) AES 2006 (all of them)
Hyperandrogenism ± hyperandrogenemia Hyperandrogenism±hyperandrogenemia Hyperandrogenism ± hyperandrogenemia
Oligo-ovulation Menstruation abnormality Ovarian dysfunction ± sonographic aspect
Sonographic aspect of poly cystic ovary

Table 1.

Different definition of polycystic ovary syndrome.

European Society for Human Reproductive Medicine.

American Society for Reproductive Medicine.

Exclusion of other androgen excess conditions is necessary for all of definition: (21-hydroxylase deficient, thyroid dysfunction, nonclassical adrenal hyperplasia, hyper prolactinemia, drug-induced androgen excess, androgenic neoplasm, Cushing syndrome, growth hormone excess).

Contrary to physicians’ and patients’ belief, weight or body mass index (BMI) had never been a part of PCOs definition.

According to epidemiological data, there is a wide variation in the prevalence of obese and non-obese PCOs women: in Korean population 20%, in Europe 27–50.5%, and in USA 67% of PCOs woman are obese [7, 8, 9, 10, 11]. Regarding to different ethnicity, the prevalence of normal weight and underweight patients with PCOs has been reported 1.5–6.6% [12, 13]. Entirely, by using Rotterdam criteria, the overall prevalence of PCOs is increasing because ovulatory or non-hyper androgen PCO patients also are considered [14].

By definition, women with BMI ≤ 25 are non-obese and with BMI > 25 considered obese.

Although at now, we have a few reports about the prevalence of non-obese PCOs patients, but attention toward those patients and their metabolic and health problems are enhanced day by day.

The pathophysiology of PCOs is multifactorial and manifests the final effect of genetic, fetal, environmental, and metabolic factors. As a result of weakness or strength of each factor, clinical and subclinical character and their response to therapeutic efforts will be different.


2. Genetic and PCOs

Obvious familial clustering of PCOs and higher prevalence of its sign and symptom, like type 2 diabetes mellitus (T2DM) and hyperandrogenemia in first-degree relatives of women with PCOs, demonstrate its genetic origin [15, 16]. Also, in the Dutch twin study, higher degree of heritability was shown [17]. Initially, autosomal dominant mode of inheritance was suggested [18]; but after a while, researches demonstrate it has more complex inheritance pattern. Despite the progress in genes or loci study, no single gene has been successfully described as the certain responsible gene among all studies [19]. According to microarray analysis results, 14 important genes were recognized: 6 genes were identified as down-regulated genes and 8 genes as up-regulated genes [20]. Another proposed genes are CYP11A, the insulin gene, and a region near the insulin-receptor gene [21]. Also, controlling genes in folliculogenesis and LH receptor and coding genes for TNF-alpha, IL-6, and IL-6 receptor can be involved in the pathogenesis of this syndrome [22].


3. Insulin and PCOs

For the first time in 1980, the relation between this syndrome and insulin was determinate [23]. Clinically insulin resistance (IR) is specified as inability of a known amount of endogenous or exogenous insulin to enhance glucose uptake and consumption. As a result of a misbelief that IR always accompanies with obesity, in clinical practice, IR is underestimated in non-obese PCO women. IR is a common character between obese and non-obese PCO patients and its overall prevalence is 50–75%. Up to 35% of PCOs women have IGTT and 7–10% are type 2 diabetes mellitus (T2DM) [24].

At now, the most used IR indices are homeostasis-model assessment (HOMA) and insulinemic 2-h area under the curve (AUCi 2 h), both derived from oral glucose tolerance test (OGTT) [25]. The 120-min glucose and insulin evaluation (HOMA-M120) is the best IR index in lean PCOs women according to Morciano et al. study [26]. Meanwhile, there are several earlier studies about IR evaluation in lean PCOs women [27, 28, 29]. Although, a study in a large group of European lean PCOs patients displayed that this group had significantly less IR compared with obese PCO women [30]; but, instead of it, there is evidence that in American and Asian PCOs women, IR is independent from BMI [31]. It seems that dietary composition and ethnic background associated with this discrepancy.

Owing to another recent study, the crucial role of insulin in PCO pathogenesis emphasized that IR shall be evaluated even in normal weight and lean PCOs patients [12].

As suggested in the earlier study [32], hyperinsulinemia stimulates ovarian P450c17 alpha activity in non-obese women with PCOs, which means more conversion of progesterone to androstenedione which is changed to testosterone. In granulosa cell, insulin intensifies their response to LH. Therefore, these cells experience premature arrest of follicular growth and abnormal differentiation, and thus anovulation. Also, elevated insulin resistance causes hyperglycemia which leads to hyperinsulinemia and it can increase LH action on theca cells and subsequent elevation in androgen level. Hyperinsulinemia, insulin resistance, and enhancement in androgen production are the famous pathophysiology triads in PCOs. From another side, elevated level of insulin prevents hepatic sex hormone-binding globulin (SHBG) production, which can lead to elevated free androgen and again elevated level of insulin, a positive feedback in an undesirable circle. Thus, IR and hyperinsulinemia are the principal pathological causes of this syndrome, and hyperandrogenemia is their consequence.

As insulin resistance has fundamental role in non-obese PCOs patients, then metformin administration have a beneficial effect on them and regulate their menstruation cycle [33]. As well, there is a new therapeutic option: inositol, a precursor component of second messenger for follicle-stimulating hormone (FSH), thyroid - stimulating hormone (TSH), and insulin receptor. This drug can overcome IR from another way [34]. It is important to mention that only 15% of women with IR are having PCOs criteria; therefore, insulin resistance cannot be the only pathophysiologic pathway [35] and metformin administration may not be effective in all of lean PCOs.


4. Androgens and PCO

About 10–12% of women in reproductive age suffer from androgen excess sign and symptom. It can be caused by androgen overproduction (from ovary or adrenal gland) or secondary to increased sensitivity of pilosebaceous unit (with normal level of androgens). Hyperandrogenemia is another hallmark of PCOs; mainly by ovarian resource and less by adrenal. In PCOs women, 60% of serum androstenedione and testosterone (T) are secreted by ovary. Surprising, ovarian androgens will not prominently affect LH production, thus an elevation in free testosterone or androstenedione will not decrease ovarian synthesis of these androgens in women, contrasting to men.

As mentioned before, in PCO women, insulin in a solitary manner or with synergetic effect of LH induces androgen production by ovaries. Even in lean PCOs women with normal metabolic insulin sensitivity and insulin levels, decline of insulin secretion with diazoxide (like metformin) prominently reduce levels of free T and androstenedione and meaningfully increased SHBG [36]. In these women, hyperandrogenemia is seen because of augmented sensitivity of their androgenic pathway to insulin and dysregulation of steroidogeneses enzymes based on genetic predisposition [37]. Therefore, even in PCOs patients with normal insulin metabolic and without clinical approved IR, local resistance in the ovaries increased androgens production [38].

Androgen excess or hyperandrogenemia (HA) in PCOs women contribute in exacerbation of metabolic abnormalities, such as insulin resistance in adipose tissue and skeletal muscle and elevation in lipid metabolism in visceral fat, decreased lipolysis in subcutaneous fat, increased low-density lipoprotein cholesterol (LDL-C) levels decreased HDL-C levels. Besides that, androgens may be involved in possible direct vascular action [39]. There are some studies, in which hyperandrogenemia was accompanying with metabolic syndrome (MetS) in non-obese PCOs more than obese PCOs women [40, 41].

Hyperandrogenemia or androgen access clinical signs are mainly cutaneous manifestations: hirsutism, acne, androgenic alopecia, acanthosis nigricans (AN), and seborrhea. In one study, their prevalence in PCOs women was: 78, 48, 31, 30, and 29% (in mentioned order) [42]. In another study, the prevalence of acanthosis nigricans in obese PCO was 42.5% compared to 28% in non-obese [43]. One published paper shows that AN is a marker of hyperinsulinemia in both obese and non-obese PCO patients rather than a sign of androgen excess and the only sex steroid associated with histological AN is dehydroepiandrosterone sulfate (DHEAS) [44].

Pharmacological management of hyperandrogenic skin symptoms has two targets: firstly, decrease the level of circulating androgens, and secondly prevent their effect at tissue level. Cyproterone acetate/ethinylestradiol has beneficial effect in non-obese PCO women with hyperandrogenic skin symptoms [45].


5. Inflammation and PCO

There are many published studies about proinflammatory or inflammatory situations in PCOs woman. Increased level of circulatory inflammatory markers like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukins (IL-16 and -18), and plasminogen activator inhibitor in PCO patients accompany with abdominal obesity and more specific with visceral fat [46]. Low-grade inflammation situation by increased level of adiponectin, resistin, IL-6, and TNF-α in non-obese PCO women have been approved [47]. Also, it has been shown that inhibition of nutrient-induced inflammation decreases ovarian androgen secretion and induces ovulation in lean PCOs woman without clinical IR or abdominal adiposity. Therefore, inflammation directly encourages ovarian dysfunction in PCOs women distinctly from insulin resistance or excess adiposity [48]. There is evidence that non-steroidal anti-inflammatory agent administration in lean PCO women can reduce androgen secretion from ovary [49].

Dose inflammation have pathophysiologic role in this syndrome or may be its consequence remain still unclear. Inflammation as a chronic immune activation, prevents ovulation, increases androgen production by ovary and adrenal gland and disrupts hormonal receptors. Most of long-term complications of PCOs like cardiovascular disease (CVD) are consequences of inflammatory state [50].

In non-obese PCO patients, visceral fat distribution, waist to hip ratio (WHR), and abdominal obesity have relation with inflammatory situation. In one study, in lean PCOs, level of white blood cell (WBC) has a positive predictive value with insulin resistance, while the neutrophil to lymphocyte ratio has a negative predictive value [51]. Also, it has been demonstrated that in clomiphene citrate (CC)-resistant patients, regardless to BMI, inflammatory markers like TNF-α are too high, and TNF-α serum level may be used as a clinical predictive indicator before CC useless administration [52].


6. Weight and PCO

Even in lean PCO women, we can see higher waist to hip ratio, greater intra peritoneal and visceral fat, and percentage of body fat in comparison with BMI matched non-PCO women. Accumulation of small subcutaneous abdominal fat in those patients shows spoiled adipogenesis and hyperandrogenism [53]. Also, abnormal gene expression in stem cell of subcutaneous abdominal fat in normoandrogen and ovulatory lean PCO women display abnormal vacuolization and angiogenesis, which may reflect metabolism alter in those women [54]. From another side, adiponectin, a protein which is involved in regulating glucose levels and fatty acid breakdown, is produced by omental fat and dysregulated by high level of insulin; thus, even in lean PCOs women, inappropriate metabolism of glucose and lipid can be explained [55]. In respect with a new randomized controlled trial, arranged and regular physical exercise can ameliorate insulin sensitivity, hyperandrogenemia, and menstrual regularity in lean PCO women [56].


7. Metabolic disorders and PCO

PCOs is considered by multiple metabolic disorders which may associate to increase risk of hypertension and cardiovascular disease. One study used menstrual irregularity as a predictive factor for assessment of cardiovascular events in a 15-year period, in PCOs women. There was an insignificant increase in overall stroke risk and in ischemic stroke risk associated with “very irregular” menstrual cycles [57]. In PCO women, higher prevalence of hypertension is related to insulin. Hyperinsulinemia have been connected with an increase in intracellular sodium and calcium, along with vascular smooth muscle hypertrophy due to insulin-like growth factor-1 (IGF-1) activity [58]. Simultaneously, androgen excess stimulates sympathetic nerve activity, as another etiology of hypertension in this population [59].

PCOs is also associated with elevated levels of plasma endothelin-1 (ET-1), one of several circulating indicators of endothelial injury and dysfunction. One study found that impairment of endothelial function is more severe in lean than obese women with PCOs, and that ET receptor downregulation plays an essential role in this probably adverse cardiovascular outcome [60].

The increase in carotid intima-media wall thickness (CIMT) in PCOs women has been associated in different studies with higher levels of insulin, hyperandrogenism, LDL level, and abdominal obesity; which is an early marker of atherosclerosis [61].

Meanwhile, impaired nitric oxide (NO) production as a consequence of elevated androgen levels in PCOs women contribute to endothelial dysfunction [62].

Elevated plasma viscosity as a result of increased plasma fibrinogen concentration in PCOs patients exacerbates vascular dysfunction because autoregulation of vasomotor tone may not be able to adjust with compromised physical properties of blood [63]. Some possible reasons for increased plasma fibrinogen are: increased inflammatory processes [64], decreased fibrinolysis [65], and as an acute phase reactant. Enhancement in fibrinogen level stimulates RBC aggregation and significantly increased resistance in blood flow [66]. Low SHBG and high insulin stimulate prothrombotic state in all of PCOs women by increased plasminogen activator inhibitor 1 (PAI-1) activity and fibrinogen in a BMI-independent way [67].

Dyslipidemia including elevated low-density lipoprotein (LDL), triglyceride levels and decreased high-density lipoprotein (HDL) are often seen in PCO women as a result of hyperandrogenism and insulin resistance in both lean and obese PCO patients [68].

Owing to many evidence about vitamin D deficiency and metabolic syndrome; there are many studies about 25(OH) D levels and PCOs. There are some evidences which support this relationship and encourage vitamin D administration in all of deficient PCOs women [69], whereas some studies do not support it [70].

From another site, insulin resistance, increased central adiposity, higher levels of testosterone, and dyslipidemia beside oxidative stress and low grade inflammation contribute to cause hepatic steatosis or fatty liver in PCOs women. Advanced stage of this disease characterized by necrosis and steatohepatitis which called non-alcoholic fatty liver disease (NAFLD) and has prevalence about 40% in lean PCOs women [71].

After blow-by-blow discussion about all of aspects in lean PCOs women, we cannot consider this syndrome as just a part of infertility or menstrual abnormality assessment, but should be accepted as an alarm sign for serious health problem.


  1. 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2745-2749. DOI: 10.1210/jc.2003-032046
  2. 2. Botsis D, Kassanos D, Pyrgiotis E, Zourlas PA. Sonographic incidence of polycystic ovaries in a gynecological population. Ultrasound in Obstetrics & Gynecology. 1995;6(3):182-185. DOI: 10.1046/j.1469-0705.1995.06030182.x
  3. 3. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology. 1935;29(2):181-191. DOI:
  4. 4. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Reviews in Obstetrics & Gynecology. 2011;4(2):45-51 PMCID: PMC3218544
  5. 5. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-47 PMID: 14688154
  6. 6. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility. 2009;91(2):456-488. DOI: 10.1016/j.fertnstert.2008.06.035
  7. 7. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: Influence of the diet. Human Reproduction. 2003;18(11):2289-2293 PMID: 14585875
  8. 8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. The Journal of Clinical Endocrinology and Metabolism. 1999;84(11):4006-4011. DOI:
  9. 9. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. The Journal of Clinical Endocrinology and Metabolism. 1998;83(9):3078-3082. DOI: 10.1210/jcem.83.9.5090
  10. 10. Kim JJ, Hwang KR, Choi YM, Moon SY, Chae SJ, Park CW, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertility and Sterility. 2014;101(5):1424-1430. DOI: 10.1016/j.fertnstert.2014.01.049
  11. 11. Kyrkou G, Trakakis E, Attilakos A, Panagopoulos P, Chrelias C, Papadimitriou A, et al. Metabolic syndrome in Greek women with polycystic ovary syndrome: Prevalence, characteristics and associations with body mass index. A prospective controlled study. Archives of Gynecology and Obstetrics. 2016;293(4):915-923. DOI: 10.1007/s00404-015-3964-y
  12. 12. Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics. 2017;296(2):363-371. DOI: 10.1007/s00404-017-4422-9
  13. 13. Sheng Y, Lu G, Liu J, Liang X, Ma Y, Zhang X, et al. Effect of body mass index on the outcomes of controlled ovarian hyperstimulation in Chinese women with polycystic ovary syndrome: A multicenter, prospective, observational study. Journal of Assisted Reproduction and Genetics. 2017;34(1):61-70. DOI: 10.1007/s10815-016-0830-1
  14. 14. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction. 2010;25(2):544-551. DOI: 10.1093/humrep/dep399
  15. 15. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:66-71. DOI: 10.1210/jc.2004-0229
  16. 16. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:14956-14960 PMCID: PMC24557
  17. 17. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2100-2104. DOI: 10.1210/jc.2005-1494
  18. 18. Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families. The Journal of Clinical Endocrinology and Metabolism. 1999;84(1):38-43. DOI: 10.1210/jcem.84.1.5382
  19. 19. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Molecular and Cellular Endocrinology. 2013;373:29-38. DOI: 10.1016/j.mce.2012.10.009
  20. 20. Panda PK, Rane R, Ravichandran R, Singh S, Panchal H. Genetics of PCOS: A systematic bioinformatics approach to unveil the proteins responsible for PCOS. Genomics Data. 2016;8:52-60. DOI: 10.1016/j.gdata.2016.03.008
  21. 21. Legro RS, Strauss JF. Molecular progress in infertility: Polycystic ovary syndrome. Fertility and Sterility. 2002;78:569-576 PMID: 12215335
  22. 22. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: An update. Reproductive Biology and Endocrinology. 2016;14(1):38-50. DOI: 10.1186/s12958-016-0173-x
  23. 23. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabolism. 1980;50:113-116. DOI: 10.1210/jcem-50-1-113
  24. 24. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in beta-cell function in functional ovarian hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 1993;76(5):1241-1247. DOI: 10.1210/jcem.76.5.8496316
  25. 25. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63 PMID: 10857969
  26. 26. Morciano A, Romani F, Sagnella F, Scarinci E, Palla C, Moro F, et al. Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertility and Sterility. 2014;102(1):250-256. DOI: 10.1016/j.fertnstert.2014.04.004
  27. 27. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257-1266 PMID: 1397698
  28. 28. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabolism. 1983;57:356-359. DOI: 10.1210/jcem-57-2-356
  29. 29. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174 PMID: 2670645
  30. 30. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, et al. Insulin sensitivity in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2942-2945. DOI: 10.1210/jc.2003-031378
  31. 31. Takeuchi T, Tsutsumi O, Taketani Y. Abnormal response of insulin to glucose loading and assessment of insulin resistance in nonobese patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24:385-391. DOI: 10.1080/09513590802173584
  32. 32. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. The Journal of Clinical Endocrinology and Metabolism. 1997;82(12):4075-4079. DOI: 10.1210/jcem.82.12.4431
  33. 33. Al-Ozairi E, Quinton R, Advani A. Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome. Fertility and Sterility. 2008;90(4):1197.e1-1197.e4. DOI: 10.1016/j.fertnstert.2007.11.041
  34. 34. Genazzani AD. Inositol as putative integrative treatment for PCOS. Reproductive Biomedicine Online. 2016;33(6):770-780. DOI: 10.1016/j.rbmo.2016.08.024
  35. 35. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertility and Sterility. 1988;50(2):197-212 PMID: 3294042
  36. 36. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertility and Sterility. 2007;88(4):10-16. DOI: 10.1016/j.fertnstert.2006.12.055
  37. 37. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. The Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1318-1323. DOI: 10.1210/jcem.86.3.7318
  38. 38. Wu XK, Zhou SY, Liu JX, Pollanen P, Sallinen K, Makinen M, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertility and Sterility. 2003;80:954-965 PMID: 14556818
  39. 39. Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Women's Health. 2009;4:583-594. DOI: 10.2217/17455057.4.6.583
  40. 40. Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. Journal of Research in Medical Sciences. 2011;16:763-769 PMCID: PMC3214394
  41. 41. Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ, et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PloS One. 2014;9(6):e99252. DOI: 10.1371/journal.pone.0099252
  42. 42. Abid Keen M, Hassan Shah I, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study. Indian Dermatology Online Journal. 2017;8(2):104-110. DOI: 10.4103/2229-5178.202275
  43. 43. IbrahimMahmoud M, Habeebc F, Kasim K. Reproductive and biochemical changes in obese and non-obese polycystic ovary syndrome women. Alexandria Journal of Medicine. 2015;51(1):5-9. DOI:
  44. 44. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis Nigricans, insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings. The Journal of Clinical Endocrinology and Metabolism. 1991;73(3):590-595. DOI: 10.1210/jcem-73-3-590
  45. 45. Bitzer J, Römer T, Lopes da Silva Filho A. The use of Cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms—A review. The European Journal of Contraception & Reproductive Health Care. 2017;22(3):172-182. DOI:
  46. 46. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT. The Journal of Clinical Endocrinology and Metabolism. 2005;90(4):2282-2289. DOI: 10.1210/jc.2004-1696
  47. 47. Y-X WANG, W-J ZHU. Evaluation of adiponectin, resistin, IL-6, TNF-α in obese and non-obese women with polycystic ovary syndrome. Journal of Reproduction and Contraception. 2012;23(4):237-244. DOI:
  48. 48. Gonzalez F, Mather KJ, Considine RV, Pardue SL, Acton AJ. Suppression of nutrient-induced inflammation with a nonsteroidal anti-inflammatory agent ameliorates ovarian dysfunction in lean insulin-sensitive women with polycystic ovary syndrome (PCOS). Fertility and Sterility. 2015;14(3):e21. DOI: 10.1016/j.fertnstert.2015.07.064
  49. 49. Gonzalez F, Considine RV, Abdelhadi OA, Acton AJ. Anti-inflammatory therapy suppresses proinflammatory cytokine secretion from mononuclear cells and reduces hyperandrogenism in lean women with polycystic ovary syndrome (PCOS). Fertility and Sterility. 2016;106(3):e32. DOI: 10.1016/j.fertnstert.2016.07.104
  50. 50. Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2015;191:15-22. DOI: 10.1016/j.ejogrb.2015.05.005
  51. 51. Tola EN, Yalcin SE, Dugan N. The predictive effect of inflammatory markers and lipid accumulation product index on clinical symptoms associated with polycystic ovary syndrome in non-obese adolescents and younger aged women. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017;214:168-172. DOI: 10.1016/j.ejogrb.2017.05.014
  52. 52. Seyam E, Hasan M, Khalifa EM, Ramadn A, Hefzy E. Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic ovary disease. Gynecological Endocrinology. 2017;8:1-7. DOI: 10.1080/09513590.2017.1320383
  53. 53. Akopians AL, Madrigal V, Fisch S, Ramirez E, Margolis D, Sarma MK, et al. Hyperandrogenism is associated with preferential fat deposition of visceral versus subcutaneous (SC) abdominal fat in lean polycystic ovary syndrome (PCOS) women. Fertility and Sterility. 2016;106(3):Supp:e31-Supp:e32. DOI: 10.1016/j.fertnstert.2016.07.102
  54. 54. Phan J, Madrigal VK, Guedikian A, Li X, Dumesic DA, Chazenbalk GD. Immunological, structural and stem cell characteristics of subcutaneous (SC) abdominal adipose in lean polycystic ovary syndrome (PCOS) women versus normoandrogenic ovulatory (NL) women. Fertility and Sterility. 2016;106(3):supp:e250. DOI: 10.1016/j.fertnstert.2016.07.722
  55. 55. Seow KM, Tsai YL, Juan CC, Lin YH, Hwang JL, Ho LT. Omental fat expression of adiponectin and adiponectin receptors in non-obese women with PCOS: A preliminary study. Reproductive Biomedicine Online. 2009;19(4):577-582 PMID:19909601
  56. 56. Bisgaard H, Dela F. Physical exercise is a help for lean women with polycystic ovary syndrome. Ugeskrift for Laeger. 2017;179(23): PMID: 28606299
  57. 57. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. The J Clin Endocrinol Metab. 2002 May;87(5):2013-17. DOI: 10.1210/jcem.87.5.8471
  58. 58. Zavaroni I, Coruzzi P, Bonini L, Mossini GL, Musiari L, Gasparini P, et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. American Journal of Hypertension. 1995;8(8):855-858. DOI: 10.1016/0895-7061(95)00152-F
  59. 59. Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? American Journal of Physiology. Endocrinology and Metabolism. 2008;294:E576-E581. DOI: 10.1152/ajpendo.00725.2007
  60. 60. Usselman CW, Taylor HS, Stachenfeld NS. Microvascular endothelial function in lean versus obese women with polycystic ovary syndrome: Role of the endothelin B receptor. Gynecological Endocrinology. 2007;23(10):604-609. DOI: 10.1096/fj.1530-6860
  61. 61. Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: Important underrecognised cardiometabolic risk factor in reproductive-age women. International Journal of Endocrinology. 2015;786362. DOI: 10.1155/2015/786362
  62. 62. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001;103(10):1410-1415 PMID: 11245645
  63. 63. Vervita V, Saltamavros AD, Adonakis G, Tsapanos V, Decavalas G, Georgopoulos NA. Obesity and insulin resistance increase plasma viscosity in young women with polycystic ovary syndrome. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology. 2009;25(10):640-646. DOI: 10.1371/journal.pone.0167290
  64. 64. Gonzalez F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300-305. DOI: 10.1016/j.steroids.2011.12.003
  65. 65. Burchall GF, Piva TJ, Linden MD, Gibson-Helm ME, Ranasinha S, Teede HJ. Comprehensive assessment of the hemostatic system in polycystic ovarian syndrome. Seminars in Thrombosis and Hemostasis. 2015. DOI: 10.1055/s-0035-1564837
  66. 66. Simmonds MJ, Milne N, Ong K, Brotherton E, McNamee AP, Horobin J, Sabapathy S. Physical properties of blood are altered in young and lean women with polycystic ovary syndrome. PLoS One. 2016;11(11):e0167290. DOI: 10.1371/journal.pone.0167290
  67. 67. Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2011;96(4):1068-1076. DOI: 10.1210/jc.2010-2279
  68. 68. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertility and Sterility. 2003;79(6):1358-1364 PMID:12798883
  69. 69. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European Journal of Endocrinology. 2009;161(4):575-582. DOI: 10.1530/EJE-09-0432
  70. 70. Rashidi H, Najafian M, Toolabi M, Safapoor N, Sadrian E, Nazari P. The relationship of serum 25-dihydroxy vitamin D3 concentrations with metabolic parameters in non-obese women with polycystic ovarian syndrome. Middle East Fertility Society Journal. 2016;21(4):264-268. DOI: 10.1016/j.mefs.2016.06.003
  71. 71. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clinical Gastroenterology and Hepatology. 2007;5(4):496-501. DOI: 10.1016/j.cgh.2006.10.010

Written By

Elham Pourmatroud

Submitted: 29 March 2017 Reviewed: 21 August 2017 Published: 20 December 2017